Alvin Shih
Director/Board Member at ZEVRA THERAPEUTICS, INC.
Net worth: - $ as of 2024-05-30
Alvin Shih active positions
Companies | Position | Start | End |
---|---|---|---|
ZEVRA THERAPEUTICS, INC. | Director/Board Member | 2024-01-19 | - |
Independent Dir/Board Member | 2024-01-19 | - | |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Director/Board Member | 2021-02-03 | - |
Chief Executive Officer | 2021-02-03 | - | |
President | 2021-02-03 | - | |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | Director/Board Member | - | - |
Career history of Alvin Shih
Former positions of Alvin Shih
Companies | Position | Start | End |
---|---|---|---|
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Director/Board Member | 2019-07-21 | 2020-09-30 |
Chief Executive Officer | 2019-07-21 | 2020-09-30 | |
President | 2019-07-21 | - | |
Enzyvant, Inc.
Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Chief Executive Officer | 2016-10-31 | 2019-02-20 |
TRAVERE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2014-04-30 | 2016-10-30 |
PFIZER, INC. | Chief Operating Officer | 2010-04-30 | 2014-04-30 |
Training of Alvin Shih
Vanderbilt University | Undergraduate Degree |
Kellogg School of Management | Masters Business Admin |
The University of Alabama School of Medicine | Doctorate Degree |
Statistics
International
United States | 11 |
Operational
Director/Board Member | 4 |
Chief Executive Officer | 3 |
President | 2 |
Sectoral
Health Technology | 6 |
Consumer Services | 4 |
Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
TRAVERE THERAPEUTICS, INC. | Health Technology |
ZEVRA THERAPEUTICS, INC. | Health Technology |
PFIZER, INC. | Health Technology |
Private companies | 4 |
---|---|
Enzyvant, Inc.
Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Health Technology |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Health Technology |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Finance |
Rare-X
Rare-X Packaged SoftwareTechnology Services Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023. | Technology Services |
- Stock Market
- Insiders
- Alvin Shih
- Experience